Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucagon on Hepatic Metabolism in T2DM After Caloric Restriction
NCT05499702Phase 2Not yet recruiting
- Start
- Dec 2027
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in type 2 diabetes mellitus (T2DM). Primary endpoint: Rate of leucine oxidation in response to rising glucagon concentrations at 240 minutes. Planned start Dec 2027; status: not yet recruiting.
02
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05499702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05499702.